抑制剂API-1靶向Pin1调控微小RNA生成并抑制肝细胞癌发展
本研究探讨Pin1调控微小RNA(miRNA)生成的机制,并评估Pin1抑制剂API-1对肝细胞癌(HCC)的抑制作用。实验证据表明,API-1通过维持磷酸化XPO5的活性构象恢复miRNA核质转运,上调抗癌miRNA生成,在体外和异种移植小鼠中抑制HCC发展。
要点
- Pin1过表达与HCC发展直接相关,API-1靶向Pin1肽基脯氨酰异构酶结构域并抑制其顺反异构活性。
- API-1对Pin1低表达和/或XPO5磷酸化低的HCC细胞不敏感。
- API-1通过维持磷酸化XPO5活性构象恢复miRNA核质转运,抑制HCC发展。
核心结论
- 实验证据表明,API-1抑制Pin1通过保留活性XPO5构象上调miRNA生成并抑制HCC发展,支持API-1作为HCC治疗药物候选,尤其对Pin1过表达、细胞外信号调节激酶激活的HCC。
研究设计与样本
- 研究为实验性研究,包含体外细胞实验和异种移植小鼠体内实验。
主要发现
- API-1抑制HCC细胞的体外增殖和迁移。
- API-1诱导的Pin1抑制对Pin1低表达和/或XPO5磷酸化低的HCC细胞不敏感。
- Pin1识别并异构化磷酸化XPO5的磷酸化丝氨酸-脯氨酸基序,使磷酸化XPO5失活。
- API-1抑制Pin1维持磷酸化XPO5活性构象,恢复XPO5驱动的前体miRNA核质转运,激活抗癌miRNA生成,导致体外HCC抑制和异种移植小鼠HCC抑制。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide, but there are few effective treatments. Aberrant microRNA (miRNA) biogenesis is correlated with HCC development. We previously demonstrated that peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (Pin1) participates in miRNA biogenesis and is a potential HCC treatment target. However, how Pin1 modulates miRNA biogenesis remains obscure. Here, we present in vivo evidence that Pin1 overexpression is directly linked to the development of HCC. Administration with the Pin1 inhibitor (API-1), a specific small molecule targeting Pin1 peptidyl-prolyl isomerase domain and inhibiting Pin1 cis-trans isomerizing activity, suppresses in vitro cell proliferation and migration of HCC cells. But API-1-induced Pin1 inhibition is insensitive to HCC cells with low Pin1 expression and/or low exportin-5 (XPO5) phosphorylation. Mechanistically, Pin1 recognizes and isomerizes the phosphorylated serine-proline motif of phosphorylated XPO5 and passivates phosphorylated XPO5. Pin1 inhibition by API-1 maintains the active conformation of phosphorylated XPO5 and restores XPO5-driven precursor miRNA nuclear-to-cytoplasm export, activating anticancer miRNA biogenesis and leading to both in vitro HCC suppression and HCC suppression in xenograft mice. CONCLUSION: Experimental evidence suggests that Pin1 inhibition by API-1 up-regulates miRNA biogenesis by retaining active XPO5 conformation and suppresses HCC development, revealing the mechanism of Pin1-mediated miRNA biogenesis and unequivocally supporting API-1 as a drug candidate for HCC therapy, especially for Pin1-overexpressing, extracellular signal-regulated kinase-activated HCC. (Hepatology 2018).
引用
- Pu W, Li J, Zheng Y, et al. Targeting Pin1 by inhibitor API-1 regulates microRNA biogenesis and suppresses hepatocellular carcinoma development. Hepatology. 2018. PMID: 29381806. doi:10.1002/hep.29819
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。